Streptococcus pneumoniae, Drug-Resistant Invasive Disease (DRSP)
Streptococcus pneumoniae causes many clinical syndromes, depending on the site of infection (e.g., acute otitis media, pneumonia, bacteremia, or meningitis).
+Resistance defined by National Committee for Clinical Laboratory Standards (NCCLS)-approved methods and NCCLS-approved interpretive minimum inhibitory concentration (MIC) standards (µg/mL) for S. pneumoniae. NCCLS recommends that all invasive S. pneumoniae isolates found to be “possibly resistant”to beta-lactams (i.e., an oxacillin zone size of less than 20 mm) by oxacillin screening should undergo further susceptibility testing by using a quantitative MIC method acceptable for penicillin, extended-spectrum cephalosporins, and other drugs as clinically indicated (12).
Probable: a clinically compatible case caused by laboratory-confirmed culture of S. pneumoniae identified as "nonsusceptible" (i.e., an oxacillin zone size of less than 20 mm) when oxacillin screening is the only method of antimicrobial susceptibility testing performed
Confirmed: a clinically compatible case that is laboratory confirmed
The difference between this case definition and the previous case definition for this condition is the inclusion of new case classifications for reporting purposes.
12. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Villanova, PA: National Committee for Clinical Laboratory Standards, 1994;14(16); NCCLS document M100-S5.
13. CDC. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. MMWR 1996;45(No. RR-1).